Research

Presentation

The Institute will be organized around 4 complementary axes, which will accelerate the implementation of genomic medicine for the benefit of patients:

1. The development of new innovative whole-genome sequencing technologies
2. The development of more predictive integrated medicine
3. The implementation of ethical reflection and of medico-economic studies devoted to genomic medicine
4. The development of new innovative therapies based on genomic data and the characterization of undifferentiated tumors or those with an unusual phenotype to improve their management

This axis is based on the 3 founding teams of the institute (GAD, CADIR, the clinical research team of CIC-BT1431, CIC-1432 in Dijon) which are recognized in the field of research in genomics or immunotherapy. These teams are the motor behind the transfer from diagnosis to research, for the benefit of patients, and work closely with the INSERM UMR 1231 and TIM-C research centers, thereby facilitating access to new technologies or new therapies.

The institute is also working with different partner research teams to ensure the successful completion of these projects.

Activities of the Institute